Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amino Acid Dosing for Growth in Premature Neonates
NCT00120926Phase 3Completed
- Sponsor
- Pediatrix Medical Group
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of Travesol in Malnutrition and extrauterine growth restriction (EUGR) (2 arms), sponsored by Pediatrix Medical Group. Primary endpoint: Growth velocity for first 28 days of life. Started Aug 2005; status: completed.
02
Drugs
Travesol
03
Conditions
Malnutritionextrauterine growth restriction (EUGR)
Beyond the preview
Go deeper on NCT00120926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00120926.